openPR Logo
Press release

Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022 Report

05-07-2018 06:28 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Breast Cancer Vaccine Market and Clinical Pipeline

“Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of the breast cancer vaccines in clinical trials are in preclinical phase followed by Phase-I trials. The advance stage of development of breast cancer vaccine in clinical trials across the globe is in Phase-III.

Download Report Sample Weblink:

For Report Sample Contact:

Table of Contents

What are Cancer Vaccines?

Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

Mechanism of Breast Cancer Vaccine
3.1 Principle Strategies for Eliciting Immune System
3.1.1 Overcoming Immune Suppression
3.1.2 Modulation of Immune Checkpoints
3.2 Immunogenicity and Responses to Therapies
3.3 Breast Cancer Therapeutic Vaccines

Global Breast Cancer Incidence
4.1 US
4.2 Europe
4.3 Asia
4.4 Rest of the World

Global Breast Cancer Vaccine Market Current Scenario
5.1 Unexplored Opportunity
5.2 Global Breast Cancer Vaccine Pipeline Overview

Need for Personalized Breast Cancer Vaccines

Global Breast Cancer Vaccine Market Dynamics
7.1 Favorable Parameters
7.2 Commercialization Challenges

Global Breast Cancer Vaccine Market Future Prospects

FDA Guideline for the Development and Marketing of Cancer Vaccines
9.1 Considerations for Both Early and Late Phase Clinical Trials
9.1.1 Patient Population
9.1.2 Monitoring The Immune Response
9.1.3 Biomarkers As Evidence Of Efficacy
9.1.4 Adjuvants Used To Stimulate Immune Response
9.1.5 Multi-Antigen Vaccines
9.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
9.1.7 Concomitant And Subsequent Therapies
9.2 Considerations for Early Phase Clinical Trials
9.2.1 Starting Dose And Dosing Schedule
9.2.2 Booster And Maintenance Therapy
9.2.3 Dose Escalation
9.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
9.3 Considerations For Late Phase Clinical Trials
9.3.1 Safety Profile From Early Phase Clinical Trials
9.3.2 Endpoints
9.3.3 Statistical Issues
9.3.4 Control Issues
9.3.5 Delayed Vaccine Effect
9.3.6 Autologous Vaccine Trials
9.3.7 Accelerated Approval Regulations

Global Breast Cancer Vaccine Clinical Pipeline by Company and Phase
10.1 Preclinical
10.2 Phase-I
10.3 Phase-I/II
10.4 Phase-II
10.5 Phase-II/III
10.6 Phase-III

Discontinued and Suspended Breast Cancer Vaccine in Clinical Pipeline by Company and Phase
11.1 Suspended
11.2 No Development Reported
11.3 Discontinued

Competitive Landscape
12.1 Advaxis
12.2 AlphaVax
12.3 AVAX Technologies
12.4 Dendreon Corporation
12.5 Galena Biopharma
12.6 Generex Biotechnology
12.7 GlaxoSmithKline
12.8 Immune Design
12.9 Imugene
12.10 Immunovative Therapies
12.11 Immunovaccine
12.12 Inovio Pharmaceuticals
12.13 Merck
12.14 NewLink Genetics
12.15 Recombio
12.16 TapImmune
12.17 ViroMed

Figure 1-1: Categorization and Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Development of a Cellular Immune Response against TAA
Figure 4-1: US andndash;Number of New Cases and Deaths of Breast Cancer, 2016
Figure 5-1: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
Figure 5-2: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
Figure 5-3: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
Figure 5-4: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
Figure 6-1: Overview of Personalized Cancer Vaccines Development
Figure 6-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 6-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 7-1: Favorable Parameters for Breast Cancer Vaccine Development
Figure 7-2: Challenges for Breast Cancer Vaccine Market
Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: AlphaVax Clinical Pipeline Overview
Figure 12-3: Galena Biopharma Clinical Pipeline Overview
Figure 12-4: Generex Biotechnology Clinical Pipeline Overview
Figure 12-5: Immune Design Clinical Pipeline Overview
Figure 12-6: Imugene Clinical Pipeline Overview
Figure 12-7: Immunovaccine Clinical Pipeline Overview
Figure 12-8: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-9: NewLink Genetics Corporation Clinical Pipeline
Figure 12-10: TapImmune Clinical Pipeline Overview
Figure 12-11: ViroMed Clinical Pipeline Overview

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022 Report here

News-ID: 1040682 • Views: 227

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report:,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases

More Releases for Cancer

Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and